Analytical Data
-
Gene name
Chordin-like 1/CHRDL1
- Application
-
Alternative Names
NRLN1; CHL; VOPT; Ventroptin; Neuralin-1; Neurogenesin-1
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q920C1
-
Expression Region
Leu272~Cys447
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Chordin-like 1 (CHRDL1) is a member of the Chordin family of proteins, which play critical roles in embryonic development and tissue homeostasis by modulating the activity of bone morphogenetic proteins (BMPs). Research on CHRDL1 has gained interest due to its implications in various biological processes, including neuronal development, osteogenesis, and the regulation of cell differentiation. CHRDL1 acts as a BMP antagonist, inhibiting BMP signaling pathways that are crucial for cell fate determination and organogenesis. Dysregulation of CHRDL1 has been associated with several diseases, particularly in cancer where aberrant BMP signaling can influence tumor progression and metastasis. The recombinant protein form of CHRDL1 is increasingly being studied for its potential therapeutic applications, allowing researchers to explore its functional properties in a controlled setting, assess its interactions with BMPs, and evaluate its impact on cellular behaviors. Understanding the mechanisms through which CHRDL1 modulates BMP signaling can also shed light on its role in developmental disorders and provide insights into novel treatment strategies for diseases associated with dysregulated BMP pathways. Overall, the study of CHRDL1 as a recombinant protein is crucial for unraveling its complex biological functions and therapeutic potential.
